For instance, cabozantinib is an oral multikinase inhibitor targeting VEGFR1/2/3, MET, and AXL and has an acceptable efficacy in patients with advanced HCC and GIST.175,176 Repotrectinib is a next-generation ROS1/TRK/ALK multitarget inhibitor that effectively treats crizotinib-resistant lung cancer with ROS1 rearrangements. This evidence concerns the gene ALK and lung carcinoma.